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The transcription factor hypoxia-inducible factor 1 (HIF1) facilitates the induction of enzymes
necessary for anaerobic glycolysis. Luo et al. (2011) now identify pyruvate kinase (PK)-M2 as an
intriguing new interacting partner for HIF1, revealing a potential mechanism for the Warburg effect,
an elevation in aerobic glycolytic metabolism frequently observed in cancer.Cells exposed to low oxygen (hypoxia)
undergo a number of phenotypic changes
in order to survive, including a shift to-
ward glycolysis, the oxygen-independent
mechanism of producing ATP. A major
factor driving increased glycolytic flux in
hypoxic cells is induction of the transcrip-
tion factor hypoxia-inducible factor 1
(HIF1), which consists of a stably ex-
pressed b subunit and an oxygen-labile
a subunit (Wang et al., 1995). Although
the oxygen-dependent hydroxylation,
ubiquitylation, and degradation of the
a subunit provide the primary means of
regulating HIF1 activity, other HIF1 modu-
lators have been described in recent
years, complicating the picture. In this
issue, Luo et al. (2011) reveal a newaspect
to this story, showing that the glycolytic
isozyme pyruvate kinase-M2 can act as
a coactivator for HIF1, greatly increasing
the transcriptional activity of HIF1.
Pyruvate kinase (PK) is the final enzyme
in glycolysis, converting phosphoenolpyr-
uvate to pyruvate with the production of
ATP. There are four forms of PK derived
from two genes: PK-L and PK-R from
PKLR and PK-M1 and PK-M2 from
PKM2. Each isozyme is subject to differentallosteric, substrate, and posttranslational
regulation,making it oneof themost highly
regulated enzymes in the glycolytic
pathway. The PK-M isoforms are pro-
duced by alternative splicing such that
exon 9 is present in M1 and exon 10 in
M2 (Mazurek, 2010). Importantly, PK-M1
is in a permanent ‘‘on’’ state with rapid
substrate turnover and ATP production,
whereas PK-M2 can switch between
low- and high-activity states, depending
on the needs of the cell. They are therefore
expressed in different cell types: M1 is
present in a number of tissue types,
including muscle and brain, and M2 in
those with high anabolic requirements,
such as proliferating cells (including all
cells during embryogenesis). In tumors,
the predominant form of PK expressed is
theM2 variant (Christofk et al., 2008; Rein-
acher andEigenbrodt, 1981). This isozyme
selection allows for the rapid proliferation
observed in tumors but, paradoxically,
may not always be consistent with the
high lactate production also observed.
The hydroxylation of HIF1a is mediated
by a family of prolyl hydroxylase domain
(PHD) enzymes (Kaelin and Ratcliffe,
2008). Of the three members (PHD1–3),PHD2 is thought to be the major hydroxy-
lase that is responsible for HIF1a stability.
Few targets have been described for the
PHDs, which is in part due to the technical
challenge of expressing fully active re-
combinant PHDs and definitively demon-
strating changes in hydroxylation state of
putative target proteins. The use of mass
spectrometry (MS) is currently the gold
standard for directly demonstrating the
hydroxylation of proline residues in a
peptide. It is often, however, not possible
to specifically assign the mass change
observed by MS to a specific proline
residue due to the oxidation of other resi-
dues that are present in the peptide.
Although this has hampered investiga-
tions into PHD substrates thus far, there
is no doubt that there are more targets
for these enzymes to be discovered.
In the current work, Luo et al. demon-
strate that PHD3-mediated hydroxylation
of PK-M2 increases the DNA binding of
HIF1a and the coactivator p300 and that
this leads to increased expression of
HIF1 target genes (Figure 1). They de-
scribe a new hypoxia response element
(HRE) in intron 1 of PKM2, showing that
this gene is also a target of HIF1. As the145, May 27, 2011 ª2011 Elsevier Inc. 647
Figure 1. Differential Regulation of HIF1a and PK-M2 by PHDs
As oxygen levels decrease, the transcription factor hypoxia-inducible factor 1 a (HIF1a) is stabilized and can strongly induce its target genes. Once levels are
close to anoxia, pyruvate kinase M2 (PK-M2) hydroxylation is decreased, and HIF1 transactivation activity is weaker. FBP, fructose 1,6-bisphosphate; GLUT1,
glucose transporter 1; HRE, hypoxia response element; LDHA, lactate dehydrogenase A; PEP, phosphoenol pyruvate; PDK1, pyruvate dehydrogenase kinase 1;
PK-M2, pyruvate kinase M2; PHD, prolyl hydroxylase domain; Ub, ubiquitin; pVHL, von Hippel Lindau protein.authors point out, this could bring about a
feedforward mechanism between these
three proteins, as EGLN3 (the gene en-
coding PHD3) is also a HIF1 target (Marx-
sen et al., 2004).
Interestingly, HIF1 does not appear to
be the only nuclear target of PK-M2. Not
only do the authors also show that
PK-M2 can also bind and enhance the
transactivation of HIF2, but a previous
study found that PK-M2 binds the devel-
opmental transcription factorOct4, result-
ing in increased target gene expression
(Lee et al., 2008). However, Luo et al. go
further here, showing that the PK-M2:
HIF1a interaction is mediated via exon
10, the specific region of PK-M2 not
present in the M1 isozyme. When the
amino acid sequence of this exon was
examined, they found that it contains an
LXXLAP motif—the sequence in HIF1a
responsible for its hydroxylation by
PHD2—and that two proline residues in
this exon are hydroxylated. When these648 Cell 145, May 27, 2011 ª2011 Elsevier Inresidues are mutated, the interaction
between HIF1a and PK-M2 is lost. The
authors therefore propose an important
new mechanistic link between oxygen
sensing and the modulation of HIF1 trans-
activation activity by implicating PHD3 in
the hydroxylation of PK-M2. Their data
strongly suggest that PHD3-dependent
hydroxylation of PK-M2 allows it to bind
HIF1a and increase its binding p300 and
the occupancy of HIF1 at target gene
promoter regions. Although the authors
observed a PK-M2/p300 interaction by
coimmunoprecipitation, there remains
the possibility that this interaction may
be indirect (through HIF1, for example).
Luo et al. present data showing that
PK-M2 hydroxylation appears to be unaf-
fected by 1% O2, when you might expect
PHD3 to be inactive (as observed with the
PHD2-mediated hydroxylation of HIF1).
Indeed, near-anorexic conditions are
required to reduce PK-M2 hydroxylation
at all. This suggests that PHD3 is stillc.very much active in hypoxia, indicating
that it has a lower KM for oxygen than
PHD2. Although not in agreement with
data from in vitro studies, this is not
unlikely. Finally, and importantly, the
authors show that depletion of either
PHD3 or PK-M2 reduces the transcription
of HIF1 metabolic target genes, providing
the link between PHD3, PK-M2, and
HIF1-mediated glycolytic control.
These data are of particular relevance
to cancer, where PK-M2 is thought to be
preferentially expressed. As HIF1 can be
stabilized in conditions in which oxygen
levels are not limiting, this phenomenon
is not necessarily limited to hypoxic cells.
Glycolytic gene expression could there-
fore be enhanced in normal oxygen
conditions, perhaps leading to the well-
known but little understood aerobic
glycolysis phenotype observed in tumors
almost 100 years ago, known as the War-
burg effect (Tennant et al., 2009). The
increased glycolytic enzyme expression
downstream of PK-M2 may well resolve
the paradox of PK-M2 expression in cells
with apparent aerobic glycolysis, but it is
unlikely that this is thewhole story. Indeed,
in a recent paper, Chen et al. show that
PHD3 interaction with PK-M2 in the
cytosol modulates PK activity, suggesting
further complexity within this story (Chen
et al., 2011). The re-expression of PK-M2
in tumors appears therefore to have two
distinct roles: the alteration of gene
expression as well as its well-described
metabolic role. However, in light of its
binding to Oct4, HIF1, and HIF2, it will be
interesting to see how extensive the role
of PK-M2 in the nucleus turns out to be.REFERENCES
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